Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

German Ortiz

Physician Assistant, Medical Steubenville, OH Physician Assistant

NPI 1629213228 CMS profile 10959773

4232 Mall Dr, Steubenville, OH 43952

Open in the dashboard

General payments

$8,386

439 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, German Ortiz of Steubenville, OH is reported in the CMS Open Payments database as having received $8,386 across 439 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,604 80
2024 General $1,457 74
2023 General $1,603 85
2022 General $1,718 88
2021 General $2,003 112

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • German Ortiz
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to German Ortiz were reported at $1,604. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year German Ortiz Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $2,003 $156 $41–$563 $132
2022 $1,718 $185 $55–$649 $149
2023 $1,603 $199 $58–$717 $160
2024 $1,457 $206 $62–$740 $164
2025 $1,604 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $1,639 45 payments
  2. Amgen Inc. $1,396 74 payments
  3. Novo Nordisk Inc $1,006 62 payments
  4. AbbVie, Inc. $953 65 payments
  5. Biohaven Pharmaceuticals, Inc. $283 11 payments
  6. Pfizer Inc. $274 19 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $247 15 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $220 9 payments
  9. Verona Pharma, Inc. $217 12 payments
  10. Axsome Therapeutics, Inc. $205 10 payments
  11. Other $1,945 117 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,377 438 payments
  2. Education $8 1 payment
Products named General payments · program years 2021–2025
  1. Repatha $1,016 58 payments
  2. Otezla $880 62 payments
  3. RYBELSUS $836 59 payments
  4. BREZTRI $762 14 payments
  5. Ozempic $727 58 payments
  6. FARXIGA $651 17 payments
  7. AIRSUPRA $546 11 payments
  8. NURTEC ODT $460 24 payments
  9. UBRELVY $367 23 payments
  10. VRAYLAR $302 25 payments
  11. Other $4,782 272 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 218 drugs

Part D claims

17,724

Median for Physician Assistant: 241

Drug cost

$1,626,654

Median for Physician Assistant: $4,110

Branded share of claims

26.9%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 123 $145,711
Rybelsus Semaglutide Brand 113 $140,752
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 147 $133,020
Jardiance Empagliflozin Brand 147 $106,857
Farxiga Dapagliflozin Propanediol Brand 120 $98,585
Eliquis Apixaban Brand 112 $93,717
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 91 $77,128
Tradjenta Linagliptin Brand 79 $75,903
Repatha Sureclick Evolocumab Brand 88 $71,482
Janumet Sitagliptin Phos/Metformin Hcl Brand 51 $58,077

The 10 drugs with the highest cost, of 218 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$36,133

Of which drugs: $5,290

Medicare patients

282

Average age 73

Services billed

1,156

153 women, 129 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 58%
Diabetes 28%
Ischemic heart disease 24%
Depression 23%
COPD 20%
Cancer 18%
Chronic kidney disease 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 33 33 $2,700
Influenza virus vaccine, quadrivalent (aiiv4), inactivated, adjuvanted, preservative free, for injection into muscle, 0.5 ml dosage 90694 Office 17 17 $1,289
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 16 88 $67
Injection, methylprednisolone acetate, 1 mg J1010 Office 15 164 $7

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $314
$314 — —
Repatha
  • Amgen Inc. $200
$200 88 —
Otezla
  • Amgen Inc. $89
$89 — —
VRAYLAR
  • AbbVie, Inc. $84
$84 — —
UBRELVY
  • AbbVie, Inc. $81
$81 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

439 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record